Search the Newsreel

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision triggered a $10 million milestone payment to MacroGenics, injecting momentum into the companies' 2022 collaboration. …

MacroGenics (MGNX) gains $86M on CDMO sale as royalties and milestones rise

MacroGenics reported a Q2 2026 profit driven by an $86.1 million gain from the sale of its CDMO operations for approximately $119.6 million. The company's total revenue significantly increased to $32.8 million due to a $24.5 million milestone from Sanofi and higher ZYNYZ royalty …

Armistice Capital (MGNX) discloses 5.0M-share MacroGenics position in 13G/A

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 5,006,752 shares of MacroGenics, Inc. common stock, which represents 7.88% of the outstanding class. Both Armistice Capital, as investment manager, and Steven Boyd, as its managing member, hold shared voting and dispositive …

MacroGenics (NASDAQ:MGNX) Posts Earnings Results, Beats Estimates By $0.39 EPS

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates

MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …

MacroGenics Q2 EPS $(0.31) misses estimate; revenue falls short

MacroGenics (NASDAQ: MGNX) reported a Q2 2026 adjusted EPS of $(0.27), significantly missing the $(0.13) estimate, and revenue of $32.832 million, falling short of the $67.456 million forecast despite a 47.62% YoY increase. The company posted a net income of $19.5 million, a turnaround …

MacroGenics : Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position Announced sale of manufacturing operations ( July 2026) for $122.5 million and transition to fully outsourced model with leaner

MacroGenics reported its second quarter 2026 financial results, highlighting a significant corporate restructuring including the sale of its manufacturing operations for $122.5 million. This transition to a fully outsourced model has streamlined the company, reducing its workforce to approximately 140 people to focus on …

MacroGenics GAAP EPS of -$1.10 misses by $1.02, revenue of $32.83M misses by $26.31M

* MacroGenics press release [https://seekingalpha.com/pr/20619132-macrogenics-reports-second-quarter-2026-financial-results-streamlined-operating-model-and] (MGNX [https://seekingalpha.com/symbol/MGNX]): Q2 GAAP EPS of -$1.10 misses by $1.02. * Revenue of $32.83M (+377.9% Y/Y) misses by $26.31M. MORE ON MACROGENICS * MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important [https://seekingalpha.com/article/4925873-macrogenics-whipsaws-on-clinical-data-but-the-big-picture-is-still-important] * MacroGenics: 'Hold' …

MacroGenics: Q2 Earnings Snapshot

MacroGenics Inc. (MGNX) reported second-quarter earnings of $19.5 million, or 31 cents per share, significantly exceeding Wall Street's expectation of a 40-cent loss per share. However, the biopharmaceutical company's revenue of $32.8 million fell short of the $44 million forecast by analysts. The earnings …

Are Investors Undervaluing Macro Bank (BMA) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value …

BH Macro Limited - Transaction in Own Shares

MacroGenics, Inc. $MGNX Shares Bought by Wasatch Advisors LP

Wasatch Advisors LP significantly increased its stake in MacroGenics (NASDAQ:MGNX) during the second quarter, purchasing an additional 459,180 shares to bring its total ownership to over 2 million shares, valued at approximately $9.3 million. This increase means Wasatch Advisors now owns 3.18% of the …

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license for a preclinical bispecific program, triggering a $10 million payment to MacroGenics. This program incorporates MacroGenics’ TRIDENT® platform and targets solid tumors. MacroGenics remains eligible for up to …

A Look at Banco Macro SA (BMA) After 4.5% Decline -- GF Value $3

MacroGenics stock rises on $10M Gilead option exercise By Investing.com

MacroGenics Inc. shares rose 4.3% after Gilead Sciences exercised its option on a preclinical bispecific program, resulting in a $10 million payment to MacroGenics. This exercise is part of a 2022 collaboration agreement, under which MacroGenics could receive up to $1.6 billion in additional …

BH Macro Limited (BHMG) Repurchases 7,500 US Dollar Shares at $4.28 Each, Adds to Treasury Stock

MacroGenics Inc expected to post a loss of 13 cents a share - Earnings Preview

MacroGenics Inc is projected to report a loss of 13 cents per share. This information is part of an earnings preview, indicating an upcoming financial announcement from the company. The full article is available through a subscription to TradingView.

Banco Macro SA (BMA) Stock News Today

This page provides the latest news and updates for Banco Macro SA (BMA) stock. It includes current market data such as stock price, market cap, and P/E ratio, alongside sections for financials, analyst ratings, and company overview. The article notes that more news will …

Banco Macro SA (BMA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Banco Macro SA (BMA), detailing its current earnings forecast score, average price target, and analyst ratings. It highlights that the stock has a strong "Buy" consensus from analysts, with specific revenue and EPS expectations for upcoming quarters. …

Acrophyte Hospitality Trust (SGX:XZL) Stock Yield Appeal Meets Cash Flow Strain

AcroMeta Group Limited Rights 2026-10.07.26 For Shares Revenue Breakdown – SGX:VDCR

MacroGenics (MGNX) Projected to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is anticipated to release its Q2 2026 earnings before market open on Thursday, August 13th. Analysts project a loss of approximately $0.08 per share and revenue of about $59.1 million. The company's prior quarter missed EPS expectations but exceeded revenue estimates, and …

Price to earnings forward of KVUTZAT ACRO LTD – TASE:ACRO

Acrophyte Hospitality Trust Reports Earnings Results for the Half Year Ended June 30, 2026

Acrophyte Hospitality Trust Suspends Distributions from First Half of 2026

BH Macro Ltd USD Revenue Breakdown – LSE:BHMU

MGNX (NASDAQ: MGNX) holder files to sell 20,166 common shares under Rule 144

A holder of MacroGenics Inc. (NASDAQ: MGNX) has filed a notice under Rule 144 to sell up to 20,166 shares of common stock through Merrill Lynch. The proposed sale date is August 3, 2026, on NASDAQ. These shares were acquired through stock plan activity …

Bank of America (NYSE: BAC) reports 4.0% beneficial stake in MacroGenics (MGNX)

Bank of America Corporation has filed an amended Schedule 13G, disclosing a beneficial ownership of 2,556,475 shares of MacroGenics, Inc. common stock, which constitutes 4.0% of the class. This stake is held through various wholly-owned subsidiaries and Bank of America reports shared voting and …

MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of "Hold" by Brokerages

MacroGenics, Inc. (NASDAQ:MGNX) has received a consensus "Hold" rating from seven brokerages, with an average 12-month price target of $5.50. This comes after some analysts raised their price targets and upgraded ratings, while others maintained a sell rating. The biopharmaceutical company recently reported a …

Are You Looking for a Top Momentum Pick? Why Banco Macro (BMA) is a Great Choice

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

Price to earnings forward of AcroMeta Group Limited – SGX:43F

MacroGenics Inc (MGNX) Financial Health: Profitability & Balance Sheet Analysis

TradingKey reports that MacroGenics Inc (MGNX) has a current financial score of 7.98, placing it 66th out of 384 in the Biotechnology & Medical Research industry, indicating a weak financial status but high operating efficiency. The company's latest quarterly revenue saw a 57.48% year-over-year …